



Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma

Swati Venkat, Arwen A. Tisdale, Johann R. Schwarz, et al.

Genome Res. 2020 30: 347-360 originally published online February 6, 2020

Access the most recent version at doi:[10.1101/gr.257550.119](https://doi.org/10.1101/gr.257550.119)

References This article cites 106 articles, 27 of which can be accessed free at:
<http://genome.cshlp.org/content/30/3/347.full.html#ref-list-1>

Open Access Freely available online through the *Genome Research* Open Access option.

Creative Commons License This article, published in *Genome Research*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>

Research

Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma

Swati Venkat,¹ Arwen A. Tisdale,¹ Johann R. Schwarz,¹ Abdulrahman A. Alahmari,¹ H. Carlo Maurer,² Kenneth P. Olive,³ Kevin H. Eng,^{4,5} and Michael E. Feigin¹

¹Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA;

²Klinikum rechts der Isar, II. Medizinische Klinik, Technische Universität München, 81675 Munich, Germany; ³Herbert Irving Comprehensive Cancer Center, Department of Medicine, Division of Digestive and Liver Diseases, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York 10032, USA; ⁴Department of Cancer Genetics and Genomics,

⁵Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA

Alternative polyadenylation (APA) is a gene regulatory process that dictates mRNA 3'-UTR length, resulting in changes in mRNA stability and localization. APA is frequently disrupted in cancer and promotes tumorigenesis through altered expression of oncogenes and tumor suppressors. Pan-cancer analyses have revealed common APA events across the tumor landscape; however, little is known about tumor type-specific alterations that may uncover novel events and vulnerabilities. Here, we integrate RNA-sequencing data from the Genotype-Tissue Expression (GTEx) project and The Cancer Genome Atlas (TCGA) to comprehensively analyze APA events in 148 pancreatic ductal adenocarcinomas (PDACs). We report widespread, recurrent, and functionally relevant 3'-UTR alterations associated with gene expression changes of known and newly identified PDAC growth-promoting genes and experimentally validate the effects of these APA events on protein expression. We find enrichment for APA events in genes associated with known PDAC pathways, loss of tumor-suppressive miRNA binding sites, and increased heterogeneity in 3'-UTR forms of metabolic genes. Survival analyses reveal a subset of 3'-UTR alterations that independently characterize a poor prognostic cohort among PDAC patients. Finally, we identify and validate the casein kinase CSNK1A1 (also known as CK1alpha or CK1a) as an APA-regulated therapeutic target in PDAC. Knockdown or pharmacological inhibition of CSNK1A1 attenuates PDAC cell proliferation and clonogenic growth. Our single-cancer analysis reveals APA as an underappreciated driver of protumorigenic gene expression in PDAC via the loss of miRNA regulation.

[Supplemental material is available for this article.]

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a 5-yr survival rate of 9% (Siegel et al. 2017). Extensive sequencing studies have uncovered recurrently mutated genes (*KRAS*, *TP53*, *SMAD4*, *CDKN2A*) and dysregulated pathways (axon guidance, cell adhesion, small GTPase signaling, protein metabolism) driving disease initiation and progression (Jones et al. 2008; Waddell et al. 2015; The Cancer Genome Atlas Research Network 2017). Gene expression profiles from hundreds of patient samples have allowed the identification of several PDAC subtypes, with implications for treatment response and patient outcome (Collisson et al. 2011; Moffitt et al. 2015; Bailey et al. 2016; Lomber et al. 2018; Tiriach et al. 2018; Maurer et al. 2019). Gene expression can be dysregulated in cancer through a variety of mechanisms, including genomic amplification/deletion, epigenetic modification, and noncoding mutations in promoters/enhancers (Khurana et al. 2013; Weinhold et al. 2014; Jones et al. 2015; D'Antonio et al. 2017; Rheinbay et al. 2017). For example, recurrent noncoding mutations in PDAC are enriched in promoters of cancer-associated genes and pathways (Feigin et al. 2017). However, our understanding of the mechanisms driving dysregulated gene expression in cancer remains incomplete. Determining the regulatory mechanisms driving dysregulated gene expression is critical to understanding disease pathogenesis. One such regulatory mecha-

nism that has recently gained recognition as a critical driver of gene expression is alternative polyadenylation (APA).

APA is a post-transcriptional process that generates distinct mRNA isoforms of the same gene as a mechanism to modulate gene expression. This includes transcripts that have identical coding sequences but vary only in the length of their 3' untranslated region (UTR) (Elkon et al. 2013; Erson-Bensan and Can 2016; Gruber and Zavolan 2019). Changes in 3'-UTR length can modulate mRNA stability, function, or subcellular localization through disruption of miRNA or RNA-binding protein regulation (Elkon et al. 2013; Mayr 2016; Tian and Manley 2017). APA is driven by a large complex of polyadenylation factors that recognize a series of highly conserved sequences within the 3' UTR on the newly synthesized pre-mRNA before cleavage and addition of the poly(A) tail (Proudfoot 2011; Elkon et al. 2013; Shi and Manley 2015). Because most transcripts contain multiple polyadenylation sites (PAS), the choice of where to cleave is a critical determinant of 3'-UTR length. In humans, a majority of genes (51%–79%) express alternative 3' UTRs, demonstrating the widespread nature of this process (Mayr 2019). Indeed, APA has roles in muscle stem cell function, cell proliferation, chromatin signaling, pluripotent cell fate, cellular senescence, and other physiological processes (Sandberg et al. 2008; Boutet et al. 2012; Lackford et al. 2014; Brumbaugh et al. 2018; Chen et al. 2018a). Recently,

Corresponding author: michael.feigin@roswellpark.org

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.257550.119>. Freely available online through the *Genome Research* Open Access option.

© 2020 Venkat et al. This article, published in *Genome Research*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

dysregulation of APA has gained recognition as a driver of tumorigenesis (Sandberg et al. 2008; Mayr and Bartel 2009; Masamha et al. 2014; Miles et al. 2016; Chen et al. 2018b). APA factor expression is altered in a variety of cancer types and promotes tumorigenesis by regulating the expression of oncogenes (via loss of miRNA regulation) and tumor suppressors (via disruption of competing-endogenous RNA cross talk) (Masamha et al. 2014; Li et al. 2015; Chen et al. 2018b; Mitra et al. 2018; Park et al. 2018). The relevance of APA in cancer was established with the discovery of a systemic increase in the usage of a proximal PAS leading to consistently shortened 3' UTRs of oncogenes such as insulin like growth factor 2 mRNA binding protein 1 (*IGF2BP1*), Rac family small GTPase 1 (*RAC1*), and cyclin D2 (*CCND2*) (Mayr and Bartel 2009; Chen et al. 2018b). Functional studies of the genes composing the APA machinery have highlighted their relevance to tumor growth; for example, in glioblastoma, overexpression of the APA factor *NUDT21* (a repressor of proximal 3'-UTR PAS usage) reduces tumor cell proliferation and inhibits tumor growth in vivo (Masamha et al. 2014). Subsequently, a number of pan-cancer analyses have used standard RNA-sequencing (RNA-seq) data to identify 3'-UTR shortening and lengthening events across cancer types (Xia et al. 2014; Le Pera et al. 2015; Grassi et al. 2016; Feng et al. 2017; Ye et al. 2018). Although these analyses have uncovered recurrent APA events across multiple tumor types, they also detected tumor type-specific events (Xue et al. 2018). Additionally, differential 3'-UTR processing has been shown to drive tissue-specific gene expression (Lianoglou et al. 2013). However, there has been no in-depth single-cancer analysis with a sufficiently large patient cohort to unravel disease-specific APA alterations. Furthermore, none of the pan-cancer studies have included PDAC owing to a lack of matched normal controls and therefore, the landscape of APA in PDAC remains completely uncharacterized.

To determine the relevance of APA in PDAC, we performed a comprehensive analysis of the changes in PAS usage using RNA-seq data from 148 PDAC tumors from The Cancer Genome Atlas Pancreatic Adenocarcinoma (TCGA-PAAD) study and 184 normal pancreata from the Genotype-Tissue Expression (GTEx) project (The Cancer Genome Atlas Research Network et al. 2013; The GTEx Consortium 2015). We performed a systems level analysis to identify trends in APA, impacts on gene expression, and effects of miRNA regulation. Our in-depth analysis reveals APA as a recurrent, widespread mechanism underlying oncogenic gene expression changes through loss of tumor-suppressive miRNA regulation in pancreatic cancer.

Results

To analyze differences in APA profiles between tumor and normal samples, we selected 148 patients out of the total 178 PDAC patients with aligned RNA-seq data from the TCGA-PAAD study. We excluded 30 patients in the cohort that did not have histologically observable PDAC tumors (The Cancer Genome Atlas Research Network 2017). Due to the paucity of RNA-seq data from matched normal tissues within the TCGA-PAAD study, we procured raw RNA-seq reads from 184 normal pancreata from the GTEx project. The library preparation and sequencing platform were identical for the TCGA-PAAD study and GTEx pancreata data (The GTEx Consortium 2015; The Cancer Genome Atlas Research Network 2017), thereby minimizing potential batch effects. Several previous studies have successfully compared TCGA and GTEx gene expression data, noting minimal batch effects when processed in an identical manner (Kosti et al. 2016; Aran et al.

2017; Zeng et al. 2019). Therefore, these data sets were processed identically and analyzed for differences in APA in our downstream analyses (Supplemental Fig. S1). To allow a rigorous comparison between GTEx normal pancreas and TCGA-PAAD tumor samples, we aligned raw reads from the GTEx RNA-seq data per the TCGA pipeline. We processed the tumor and normal aligned files to generate coverage files that were used to identify 3'-UTR differences. We assessed the extent of differential batch effects by comparing the variation in expression of housekeeping genes between the two data sets (Eisenberg and Levanon 2003). We computed the median expression (\log_2 [normalized counts]) of housekeeping genes from our coverage data and found a high correlation between the tumor and normal data sets (Pearson $R=0.91$, $P<2\times 10^{-16}$) (Supplemental Fig. S2A), suggesting that the two data sets are comparable. The coverage data were used as an input for the Dynamic Analysis of Alternative Polyadenylation from RNA-seq (DaPars) algorithm (Xia et al. 2014). DaPars is a regression-based algorithm that performs de novo identification of APA events between two conditions using standard RNA-seq data (Masamha et al. 2014; Xia et al. 2014; Chen et al. 2018b). DaPars generates a Percentage Distal Usage Index (PDUI) score for a given gene for every sample. The PDUI score quantifies the relative poly(A) site usage for that gene in the sample by computing the abundances of 3'-UTR long and short forms. Genes favoring distal PAS usage (long 3' UTRs) have PDUI scores near 1, whereas genes favoring proximal PAS usage (short 3' UTRs) have PDUI scores near 0. The final output was a PDUI matrix containing 2573 unique genes as rows and tumor/normal sample in each column (total 148 tumor + 184 normal = 332 columns). To compare 3'-UTR changes for a given gene between tumor and normal samples, the PDUI scores for the gene were averaged over tumor (MeanPDUI_T) and normal (MeanPDUI_N) samples. A change in the mean PDUI score between tumor and normal samples for each gene (Δ PDUI = MeanPDUI_T - MeanPDUI_N) was calculated and used as a measure of tumor-associated 3'-UTR shortening or lengthening.

Integrative analysis of GTEx and TCGA-PAAD RNA-seq data identifies 3'-UTR shortening events associated with PDAC

To determine an appropriate Δ PDUI threshold to identify shortened/lengthened genes, we performed a permutation test ($n=10,000$) and computed the adjusted P -values (P_{adj}) for ± 0.05 , ± 0.1 , and ± 0.15 thresholds. For a threshold of ± 0.05 , 23.8% of genes showed $P_{\text{adj}}>0.05$, suggesting that this threshold can lead to multiple false positives. However, zero genes showed $P_{\text{adj}}>0.05$ for the ± 0.1 and ± 0.15 thresholds (Supplemental Fig. S2B,C). Therefore, we chose Δ PDUI = ± 0.1 as a stringent threshold to identify shortened/lengthened genes with minimum false positives/negatives. To determine the extent of APA-mediated 3'-UTR shortening and lengthening in PDAC, we compared the PDUI scores for each gene between the tumor and normal samples (Fig. 1A,B). Although the majority of genes do not undergo changes in APA, PDAC patients are characterized by a greater number of significant 3'-UTR shortening events (red dots, $n=266$) as compared to significant lengthening events (blue dots, $n=186$) (Fig. 1B). A higher number of 3'-UTR shortening events compared to lengthening events in PDAC is consistent with patterns observed in multiple pan-cancer analyses (Mayr and Bartel 2009; Xia et al. 2014; Xiang et al. 2018). The tumor-associated shortening and lengthening events were predominantly 100–300 bp and 200–300 bp in length, respectively (Fig. 1C). Among the genes found to have significantly shortened 3'-UTR lengths were many known PDAC growth-




Figure 1. Integrative analysis of RNA-seq data identifies 3'-UTR alterations associated with PDAC. (A) A plot of PDIU score of each gene in human tumor and normal samples. Dashed lines represent 0.1 cutoffs. Blue dots represent 3'-UTR-lengthened genes, and red dots represent 3'-UTR-shortened genes. (B) A volcano plot denoting 3'-UTR-shortened (red) and -lengthened (blue) gene hits (FDR < 0.01) whose $|\Delta\text{PDIU}| > 0.1$. (C) A plot showing the number of base pairs lost/gained by 3'-UTR-altered genes. (D) UCSC Genome Browser plot depicting the 3'-UTR RNA-seq density profile of two 3'-UTR-shortened genes (*FLNA* and *PAF1*) to highlight the coverage differences between tumor (orange) and normal (purple) patient samples. (E) UCSC Genome Browser plot highlighting the 3'-UTR profile differences between *FLNA* and *PAF1* in a microdissected data set in patient tumor (red) and stroma (blue). (F) 3' RACE of altered PDAC-associated genes in MIA PaCa-2 and Suit2 cells (representative images, $n=3$). Approximate length of the 3'-UTR form is denoted beside each band. (G) 3' RACE of select genes in primary patient samples (P1, P2, P3).

promoting genes, including PAF1 homolog, Paf1/RNA polymerase II complex component (*PAF1*), filamin A (*FLNA*), enolase 1 (*ENO1*), Ral guanine nucleotide dissociation stimulator (*RALGDS*), thyroid hormone receptor interactor 10 (*TRIP10*), and aldolase, fructose-bisphosphate A (*ALDOA*). *ALDOA* and *PAF1* have recently been described as oncogenes in PDAC (Dey et al. 2014; Vaz et al. 2014; Ji et al. 2016; Nimmakayala et al. 2018), whereas *ENO1*, *RALGDS*, *TRIP10*, and *FLNA* are known to mediate pancreatic cancer cell proliferation, survival and migration (Chien and White 2003; Li et al.

2009; Mihaljevic et al. 2010; Hsu et al. 2011; Zhou et al. 2011; Capello et al. 2016). We did not detect 3'-UTR alterations in recurrently mutated PDAC genes, reflecting the predominant role of APA in regulating gene expression rather than gene function. We visualized the 3'-UTR profiles of these genes between TCGA and GTEx samples to confirm 3'-UTR shortening (see *FLNA*, *PAF1* as examples) (Fig. 1D).

PDAC samples are often characterized by substantial stromal contamination (Maurer et al. 2019); therefore, we sought to

determine if significant APA events were present in the stroma or the tumor epithelium. First, we determined for every significant gene hit in our analysis whether sample purity is correlated with the PDUI score. The measure of purity considered for each sample was the pathologist-reviewed tumor cellularity score (The Cancer Genome Atlas Research Network 2017). However, none of our significant gene hits showed a significant correlation (Pearson's $R > 0.3$, $P < 0.05$) between PDUI score and tumor purity. We then analyzed PDUI changes in a subset of 69 high purity TCGA-PAAD tumor samples (>33% tumor content) (The Cancer Genome Atlas Research Network 2017). Eighty-nine percent of gene hits from our original analysis showed up as significant hits in the high purity data set, suggesting that the majority of the detected APA changes were not attributable to stromal contamination (Supplemental Fig. S3A,B). We further addressed this concern by visualizing the 3'-UTR profile of our candidate genes in an independent data set containing RNA-seq information from 65 matched human PDAC samples with microdissected tumor epithelium and stroma (Maurer and Olive 2019; Maurer et al. 2019). As an example, Figure 1E shows the differential 3'-UTR shortening of *FLNA* and *PAF1* in patient tumor epithelium (tumor cells) as compared to the matched stroma.

We validated the presence of alternative 3'-UTR forms for several APA-regulated candidate genes by 3' RACE (rapid amplification of 3' ends) in two human pancreatic cancer cell lines (Suit2, MIA PaCa-2) and primary patient samples (Fig. 1F,G). These genes included the previously described PDAC growth-promoting genes, as well as the spermine/spermidine N1-acetyltransferase 1 *SAT1*, and protein phosphatase 2 regulatory subunit Bdelta (*PPP2R2D*). *SAT1* modulates cell migration and resistance in multiple tumor types, whereas *PPP2R2D* is a component of the tumor-suppressive phosphatase PP2A (Vandenberg 2008; Seshacharyulu et al. 2013; Brett-Morris et al. 2014; Phanstiel 2018; Yu et al. 2018; Fahrman et al. 2019). With the exception of *PPP2R2D*, which displayed significant 3'-UTR lengthening and down-regulation in tumors, all of the validated genes were significantly shortened and overexpressed in the TCGA-PAAD data set. We detected 3'-UTR short and long forms via 3' RACE. The short 3'-UTR form for the majority of the shortened genes predominated over the long form (Fig. 1F, G). *ENO1* showed a single 3'-UTR form suggesting that this is the predominant form in cancer cells. In contrast, *PPP2R2D* showed an increased proportion of the 3'-UTR long form in PDAC cell lines and patient samples as compared to the short form, suggesting greater use of the distal PAS for this putative tumor-suppressive gene. For every candidate, we successfully identified PAS sites within its 3'-UTR sequence that matched the expected position of proximal and distal PAS in the detected 3' RACE forms (Supplemental Fig. S3C). Therefore, a large-scale comparison of 3'-UTR alterations can identify tumor epithelium-specific changes from the TCGA and GTEx data sets, and these 3'-UTR forms can be detected in cell models and patient samples.

3'-UTR changes are widespread among PDAC patients and enriched in PDAC pathways

To visualize the landscape of APA across PDAC, we clustered patients (columns) based on change in PDUI score (tumor – normal mean; Δ PDUI) for 3'-UTR-altered genes (rows) (Fig. 2A). This analysis uncovered a subset of genes ($n = 68$) that showed 3'-UTR shortening (red) in >90% of patients, highlighting the widespread nature of APA across PDAC. A smaller subset of 3' UTRs ($n = 26$, bottom heatmap) was recurrently lengthened (blue) in the tumor co-

hort. Hierarchical clustering identified multiple patient subgroups characterized by 3'-UTR alterations of specific gene sets (Subgroups 1–5). Subgroup 5 was enriched in shortened 3' UTRs and contained relatively few lengthening events. In contrast, Subgroup 1 displayed fewer 3'-UTR shortening events and was enriched in 3'-UTR lengthening. Subgroups 2–4 were characterized by shortening events in specific subsets of genes. These subgroups did not correlate with the mutational status of recurrently mutated PDAC genes (*KRAS*, *CDKN2A*, *SMAD4*, *TP53*), nor did they associate with previously described PDAC subtypes.

Pathway analysis of the significantly altered genes revealed enrichment for mRNA 3' end processing and splicing, as well as smooth muscle contraction and platelet activation. Similar pathways have been found by pan-cancer APA analyses, concordant with the presence of recurrent APA events across multiple cancer types (Lianoglou et al. 2013; Xia et al. 2014). However, we observed further enrichments in PDAC-associated pathways, including protein metabolism, signaling by receptor tyrosine kinases, signaling by RHO GTPases, JAK-STAT signaling, and cell–extracellular matrix interactions (Fig. 2B). Therefore, APA alterations may regulate the activity of PDAC-promoting pathways.

3'-UTR shortening identifies a poor prognostic cohort in PDAC patients

Next, we asked whether APA events added additional prognostic information to PDAC patient outcomes above the usual demographic and clinical factors: age, race, sex, stage, grade, and surgical outcome. We selected genes with significant 3'-UTR alterations and univariate prognostic value, defining prognostic classes based on multivariate clustering (Fig. 3A). This segregated patients into three cohorts based on their 3'-UTR patterns (long in blue; short in red). Cohort A was predominantly associated with proximal PAS usage of genes from Groups 1 and 3, whereas Cohort C was associated with distal PAS usage of the same genes. For Group 2 genes, distal PAS usage was predominant in Cohort A, but proximal PAS usage was predominant in Cohort C. Neither patient cohort correlated with any of the known PDAC tumor subtypes. Cohorts A and C displayed significant differences in overall survival, with patients in Cohort C living significantly longer than those in Cohort A ($P = 0.003$) (Fig. 3B). Therefore, patterns of APA can be used as an independent prognostic indicator in PDAC.

Heterogeneity of proximal PAS usage of metabolic genes in PDAC patients

Processes generating genetic and epigenetic heterogeneity can drive tumor evolution (Easwaran et al. 2014; McGranahan and Swanton 2017; Hinohara and Polyak 2019). We hypothesized that APA could represent such a process, creating a diverse set of 3'-UTR forms and allowing cancer cells to select for those that promote their survival and propagation. To examine this heterogeneity, we compared the variance of proximal PAS usage across patients in any given gene between tumor and normal samples. *ALDOA* is shown as an example gene that exhibited a tight distribution of PAS usage across normal as well as patient tumors (Fig. 4A). The left shift of the tumor sample mean score represents an increased proximal PAS usage signifying the expected shortening of the *ALDOA* 3' UTR. However, for *FLNA*, although the normal samples had a tight distribution, PDAC patients showed greater heterogeneity in PAS usage (Fig. 4B). An analysis of heterogeneity in PAS usage for all genes revealed that although the majority of genes did not show a significant change between normal and




Figure 2. 3'-UTR changes are widespread among PDAC patients and enriched in PDAC pathways. (A) The heatmap shows genes (rows) undergoing 3'-UTR shortening (red) or lengthening (blue) in each patient tumor (columns) compared to median score in normal pancreas for that gene. The profile of *KRAS*, *CDKN2A*, *TP53*, and *SMAD4* mutations as well as tumor subtype is shown in the context of distinct APA-derived patient subgroups. (B) Significantly enriched (FDR < 0.05) reactome pathways associated with 3'-UTR-altered genes.

tumor conditions, 89 genes showed greater heterogeneity in tumor (orange) samples and only eight genes showed greater heterogeneity in normal (purple) samples (Fig. 4C). This heterogeneity was not attributable to intrinsic differences between the TCGA and GTEx data sets, because none of the 215 housekeeping genes in the data set showed differences in heterogeneity in the extent of proximal PAS usage (Zhu et al. 2008; Eisenberg and Levanon 2013). The subset of 89 genes was enriched in metabolic genes,

specifically amino acid transporters and purine metabolism. Increased heterogeneity of PAS usage in PDAC patients suggests a possible role of PAS usage plasticity in promoting cancer cell survival and progression.

APA drives altered protein expression in PDAC

To determine whether the identified APA events drive altered gene expression in PDAC, we computed differential gene expression between normal (GTEx) and tumor (TCGA-PAAD) tissues. This allowed association studies between specific APA events and changes in gene expression. Among 3'-UTR-shortened genes, 76 were significantly up-regulated, and 50 genes were significantly down-regulated in tumors (Fig. 5A,B). Increased gene expression in the subset of 76 genes conforms to the expectation that 3'-UTR-shortened genes can escape miRNA regulation leading to increased gene expression (Lee and Dutta 2007; Mayr et al. 2007; Mayr and Bartel 2009). However, the association of 3'-UTR-shortened genes with up-regulation was not statistically significant (Fisher's exact test, $P = 0.09$). 3'-UTR-lengthened genes showed a similar number of significantly up-regulated ($n = 42$) and significantly down-regulated ($n = 41$) genes, consistent with pan-cancer analyses, and most likely reflective of positive and negative regulation by RNA-binding proteins (Matoulikova et al. 2012; Pereira et al. 2017; Chen et al. 2018a). To experimentally validate the relationship between APA and protein expression, we performed luciferase reporter assays in MIA PaCa-2 cells, comparing protein expression driven by short and long 3' UTRs (Fig. 5C). We focused on the candidate oncogenes and tumor suppressors validated by 3' RACE and that showed significant association between 3'-UTR changes and gene expression in tumors. These candidates included *ALDOA*, *FLNA*, *PAF1*, *TRIP10*, *ENO1*, *SAT1* (shortened and up-regulated in tumors), and *PPP2R2D* (lengthened and down-regulated in tumors). We also included *RALGDS*, which is shortened

but does not show altered expression in tumors. We cloned the short and long 3' UTRs of each gene (estimated via 3' RACE) downstream from a *Renilla* luciferase reporter and measured luminescence as a readout of protein expression (Fig. 5C). To ensure that the long 3'-UTR form for each reporter gene remained intact (i.e., did not undergo APA-mediated shortening upon transfection into cells), we mutated their functional proximal PAS. For all genes tested except *ENO1* and *RALGDS*, the short 3'-UTR form showed




Figure 3. APA events identify a poor prognostic cohort in PDAC patients. (A) Patients were clustered based on 3'-UTR short (red) and long forms (blue) of 3'-UTR-altered genes (clustered into gene Groups 1, 2, and 3) and segregated into patient Cohort A (blue), patient Cohort B (black), and patient Cohort C (green). (B) Kaplan–Meier survival plot for patient Cohort A (blue), patient Cohort B (black), and patient Cohort C (green): (*) $P < 0.05$.

significantly increased luminescence compared to the long 3'-UTR form (Fig. 5D). As predicted, the 3'-UTR short and long forms of *RALGDS* showed similar expression. In contrast to our expectations, the short form of *ENO1* showed decreased protein expression suggesting that 3'-UTR shortening is not the sole mechanism regulating protein abundance of *ENO1* in PDAC. To further show that the expression changes driven by the short and long 3'-UTR forms are governed by the sequence content and not simply a function of 3'-UTR length, we cloned the reverse complement of the long 3'-UTR segment of *PAF1* downstream from its short 3' UTR. The proximal PAS was mutated to prevent APA-mediated shortening of this control construct (Supplemental Fig. S4A). As expected, this construct showed similar luminescence as the short 3'-UTR form, suggesting that the observed expression differences are primarily a function of sequence content within the long 3' UTR (Supplemental Fig. S4B). These findings reinforce the observation that gene regulation is 3'-UTR sequence-dependent and that shorter 3' UTRs do not always increase protein expression (Mayr and Bartel 2009). Overall, the above results show that APA-mediated 3'-UTR alterations can regulate the protein expression of growth-promoting genes in PDAC cells.

We next sought to determine the mechanism underlying the 3'-UTR-mediated gene regulation of the PDAC oncogene *ALDOA*. Given that miRNAs primarily destabilize their target mRNA and that *ALDOA* undergoes 3'-UTR shortening and up-regulation, we searched the *ALDOA* 3' UTR for putative miRNA binding sites that would be lost upon PDAC-associated shortening (Fig. 5E). We identified the tumor-suppressive miRNA miR-122 within this lost region; miR-122 is expressed in PDAC cell lines (Tsai et al. 2009; Zhang et al. 2009). Mutation of the miR-122 site within the long 3' UTR of *ALDOA* significantly restored protein expression (Fig. 5F). Therefore, altered APA can regulate oncogene ex-

pression in PDAC through modulation of available regulatory miRNA binding sites.

APA-mediated loss of tumor-suppressive miRNA binding sites is associated with poor patient outcome

To assess global patterns of APA-mediated miRNA binding site loss, we searched for highly conserved miRNA binding sites (conserved across human, mouse, rat, dog, and chicken) within the lost 3' UTRs of all shortened genes. This analysis revealed that 42% of genes lost at least one highly conserved miRNA binding site (Fig. 6A), suggesting that alteration of the miRNA binding site repertoire is a common mode of APA-mediated regulation. Next, we sought to determine if any miRNA families were




Figure 4. PDAC patients show substantial heterogeneity in the extent of proximal PAS usage of metabolic genes. (A) Example of a 3'-UTR-shortened gene (*ALDOA*) that has a tight distribution of its proximal PAS usage in normal pancreas (purple) as well as PDAC patients (orange). (B) A 3'-UTR-shortened gene (*FLNA*) that has a tight distribution in normal pancreas (purple); however, the extent of proximal PAS usage varies greatly across PDAC patients (orange). (C) Plot of variance in PDIU for all genes between tumor and normal. Purple dots represent genes with high variance in normal samples, and orange dots represent genes with high variance in tumor samples. Dashed lines represent 0.015 and -0.015 cutoffs.




Figure 5. APA drives altered protein expression in PDAC. (A) Log fold change in gene expression is plotted against Δ PDIU for 3'-UTR-altered genes. Overexpressed genes (red dots) and underexpressed genes (blue dots) on the *left* represent 3'-UTR-shortened hits, whereas those to the *right* represent 3'-UTR-lengthened hits. (B) Quantification of 3'-UTR-altered genes that are overexpressed (red) or underexpressed (blue) in PDAC tumors. (C) Schematic illustrating the luciferase reporter constructs. (D) Normalized fold expression change of the luciferase reporter (short 3' UTRs/long 3' UTRs) for the selected list of 3'-UTR-altered genes ($n=3$). The long 3'-UTR expression for each gene is normalized to 1. Each whisker plot denotes the median as the center line and the minimum and maximum values as the whiskers: (*) $P<0.05$; (**) $P<0.01$; (***) $P<0.005$; (****) $P<0.001$. (E) Schematic showing the *ALDOA* 3' UTR with positions of conserved miRNA sites as well as the miRNA mutant construct used. (F) Fold expression change of miRNA mutant construct compared to the PAS mutant in luciferase assays ($n=3$). The PAS mutant expression is normalized to 1.

preferentially lost in shortened 3' UTRs of PDAC patients. We computed an index for repression for each miRNA family as a function of the miRNA site context scores (obtained from TargetScan) and the abundance of the 3'-UTR form containing that site. This index was then compared between PDAC patients and normal controls to yield a Z-score. A lower Z-score for a miRNA family reflects preferential loss of its binding sites because of 3'-UTR shortening. We focused on the top eight miRNAs, because after the eighth miRNA, all subsequent significantly lost miRNAs had similar Z-scores (near -1) and all eight are expressed in pancreatic cancer cell lines (Zhang et al. 2009). Six of these top eight miRNAs have been implicated as tumor suppressors in PDAC, including miR-329 and miR-133a (Fig. 6B; Dangigirimella et al. 2011; Qin et al. 2014; Wang et al. 2016; Baradaran et al. 2019; Wang et al. 2019). These results suggest that APA regulates oncogenic gene expression through preferen-

tial loss of tumor-suppressive miRNA binding sites and may therefore confer a selective advantage to the cell.

Next, we determined whether loss of specific miRNA sites associated with 3'-UTR alterations is associated with patient outcome. We quantified loss of highly conserved miRNA binding sites for each patient as a function of the extent of proximal PAS usage in all genes that lost those miRNA sites (Methods). Clustering in the miRNA feature space revealed three patient groups (Fig. 6C) with significant differences in overall survival ($P=0.012$ between Clusters 1 and 3) (Fig. 6D). We also performed the analysis of deviance test of the nested Cox regression model: clinical variables versus clinical+miRNA clusters. We found that addition of miRNA clusters significantly improved the model. In terms of magnitude of effect, the hazard ratios associated with the miRNA clusters (Cluster 1/Cluster 3 as reference) were $HR=0.59$ and $HR=0.44$. For context, the strongest significant clinical effect is $HR=0.52$ for R0 surgical status. This suggests the miRNA-usage-based modeling is at least as strong as clinical variables. The miRNAs most significantly associated with the patient clusters included miR-133a, miR-124, miR-421, miR-143, and miR-505. Binding sites for each miRNA were preferentially lost from Cluster 1 as compared with Cluster 3, suggesting that loss of these regulatory sites correlates with poor survival of PDAC patients (Fig. 6E). Indeed, miR-133a, miR-124, and miR-143 are known tumor suppressors in PDAC, again supporting the role of APA in selective loss of tumor-suppressive miRNA binding sites (Kent et al. 2010; Hu et al. 2012; Kojima et al. 2012; Pham et al. 2013; Qin et al. 2014; Schultz et al. 2014; Wu et al. 2018).

The APA-regulated gene *CSNK1A1* is required for proliferation and clonogenic growth of PDAC cells

Our analyses revealed APA-mediated regulatory changes in genes known to promote PDAC pathogenesis. We hypothesized that our altered gene list may also contain growth-promoting genes not previously implicated in PDAC biology, and therefore new therapeutic targets. We focused on the subset of druggable genes that were significantly shortened and up-regulated in PDAC. This analysis identified *CSNK1A1*, the gene encoding the serine/threonine kinase casein kinase 1 alpha 1 (CSNK1A1, also known as CK1alpha or CK1a). CSNK1A1 regulates the Wnt/ β -catenin signaling pathway and has dual functions in cell cycle progression and cell division (Knippschild et al. 2005; Schittek and Sinnberg 2014; Cai et al. 2018). CSNK1A1 is known to influence tumor progression; however, its role as a tumor suppressor or oncogene is




Figure 6. APA-mediated loss of tumor-suppressive miRNA binding sites is associated with poor patient outcome. (A) Number of genes that lose highly conserved miRNA binding sites because of 3'-UTR shortening. The percentage of genes that lose at least one miRNA binding site is indicated above the bracket. (B) Highly conserved miRNA families were plotted against their Z-score, an index of the lost binding sites in which a more negative Z-score indicates more significant binding site loss. (C) t-SNE plot depicting TCGA patient clusters in the highly conserved miRNA feature space. (D) Kaplan-Meier survival plot for the three patient clusters identified in C: (*) $P < 0.05$ for Cluster 1 to Cluster 3 comparison. (E) Heatmap depicting the association of miRNA binding site loss (miR score) with patient clusters.

tumor type-dependent (Järås et al. 2014; Schitteg and Sinnberg 2014; Lantermann et al. 2015; Cai et al. 2018), and *CSNK1A1* has no known roles in PDAC. *CSNK1A1* has very low gene expression in normal pancreas but is overexpressed in PDAC (Jiang et al. 2018). We found that *CSNK1A1* shows significantly higher expression in the PDAC epithelium as compared to precursor lesions—preinvasive pancreatic intraepithelial neoplasia (PanIN) (Fig. 7A) and intraductal papillary mucinous neoplasia (IPMN). We found no significant difference in *CSNK1A1* expression in the stroma between PDAC and precursor lesions. 3' RACE showed that *CSNK1A1* has both the short and long 3'-UTR forms in PDAC cells as predicted by our computational analysis (Supplemental Fig. S5A).

to provide genetic evidence for the role of *CSNK1A1* in PDAC cell growth, we knocked down *CSNK1A1* in Suit2 and MIA PaCa-2 cells with three short hairpin RNAs (shRNA) (Fig. 7B; Supplemental Fig. S5B). *CSNK1A1* knockdown decreased both cell proliferation and clonogenic growth of PDAC cells (Fig. 7C–E; Supplemental Fig. S5C,D), with Suit2 cells showing increased sensitivity to *CSNK1A1* loss. The strongest phenotypic effects were associated with the most efficient knockdown (shRNA 3) in both cell lines. We then investigated the potential of *CSNK1A1* as a pharmacological target in PDAC biology with the widely used small molecule inhibitor D4476 (Rena et al. 2004; Lantermann et al. 2015; Jiang et al. 2018). In concordance with the genetic evidence, although MIA PaCa-2 and Suit2 cells were both sensitive to D4476 treatment, Suit2 cells displayed a 10-fold lower IC₅₀ (Fig. 7F). Both cell lines also showed dose-dependent decreases in cell proliferation (Fig. 7G; Supplemental Fig. S5E) and clonogenic growth in the presence of the inhibitor (Fig. 7H,I; Supplemental Fig. S5F). Therefore, we identify *CSNK1A1* as a putative drug target in PDAC and reveal the potential of cancer-specific APA analyses to identify mechanisms of altered gene expression driving cancer pathogenesis.

Discussion

Dysregulated gene expression is a cardinal feature of cancer (Yaffe 2019). However, how gene expression is altered in cancer and whether the processes driving this dysregulation can be targeted therapeutically are areas of active investigation. APA has recently been identified as a candidate driver of gene expression dysregulation. APA factors frequently show aberrant expression in cancer, modulate the expression of known oncogenes and tumor suppressors, and knockdown studies have highlighted their relevance to




Figure 7. CSNK1A1 is required for cell proliferation and is a putative drug target in PDAC. (A) A plot showing CSNK1A1 gene expression (in transcripts per million) in PDAC (red) as compared to PanIN lesions (green) in the epithelium and stroma from microdissected samples: (****) $P < 0.001$. (B) A representative blot confirming CSNK1A1 knockdown in Suit2 cells with a nontargeting control shRNA (Con shRNA) or with one of three different shRNAs targeting CSNK1A1: $n = 3$. ACTB (also known as actin beta) is shown as a loading control. (C) Cell proliferation of Suit2 control and CSNK1A1-knockdown cells: $n = 3$; (***) $P < 0.005$. (D) Clonogenic growth assay of control and CSNK1A1-knockdown cells: $n = 3$. (E) Quantification shows the number of colonies in D: $n = 3$; (****) $P < 0.001$. (F) Dose-response of MIA PaCa-2 (purple) and Suit2 (red) cell lines to the CSNK1A1 small molecule inhibitor, D4476: $n = 3$; (****) $P < 0.001$. (G) Cell proliferation of Suit2 cells treated with indicated doses of D4476: $n = 3$; (****) $P < 0.001$. (H) Clonogenic growth assay of Suit2 cells treated with indicated drug doses. (I) Quantification shows the number of colonies in H: (***) $P < 0.005$; (****) $P < 0.001$.

To our knowledge, this study represents the first global, in-depth, single-cancer view of APA, and the first examination of APA in PDAC clinical samples. The only previous study of APA in PDAC showed gemcitabine-induced 3'-UTR shortening of the transcription factor ZEB1 in the context of drug resistance (Passacantilli et al. 2017). Previous APA analyses combined multiple tumor types and used tumor-adjacent tissue as a "normal" control. However, matched tumor-adjacent normal tissues are known to represent a state that significantly differs from healthy, normal tissues and may therefore miss critical APA events (Aran et al. 2017). Furthermore, there are insufficient numbers of tumor-adjacent

pancreatic samples within TCGA for a statistically stringent analysis. Therefore, we attempted to address these issues by using normal pancreas RNA-seq information from the GTEx project. A limitation of comparing independently collected data sets is the inherent disparity between them (Lappalainen et al. 2013). We attempted to rectify this by (1) confirming that the two data sets underwent identical library preparation methods on the same type of sequencing platform; (2) following identical data processing pipelines from the raw sequencing data to generate the coverage data; and (3) validating our top hits in an independent microdissected data set. Consistent with previous publications comparing TCGA

and GTEx data sets, we compared the expression of housekeeping genes between the two data sets and observed minimal differences. Because batch effects cannot be completely ruled out, we performed experimental validation of several candidate APA-regulated genes, including *PAF1* and *ALDOA*, highlighting the robustness of our approach and relevance of our findings to PDAC biology. Furthermore, this approach will allow the analysis of APA in other tumor types for which little tumor-adjacent material is present in TCGA.

Multiple insights from our analyses are noteworthy. We find that APA events are recurrent and widespread across PDAC patients. For example, 68 genes were shortened and 28 genes were lengthened in >90% of the patient cohort. This supports the conjecture that APA dysregulation is a frequent event in PDAC. In support of this hypothesis, we find that several APA factors are highly expressed in PDAC, including *CSTF2* (Supplemental Fig. S6). *CSTF2* has previously been implicated as a promoter of lung and bladder cancer, through the regulation of *ERBB2* and *RAC1* 3' UTRs, respectively (Chen et al. 2018b; Mitra et al. 2018). We find frequent 3'-UTR alterations in several PDAC-relevant genes whose mechanisms of regulation were previously unknown, including *PAF1*, *ALDOA*, and *FLNA*. Many of the shortened 3' UTRs showed increased gene expression, providing the first collection of 3'-UTR alterations that correlate with gene expression changes in PDAC. We were able to functionally validate these through luciferase reporter assays, highlighting the robustness of our analysis. Consistent with pan-cancer APA analyses, we find enrichment for pathways such as smooth muscle contraction and mRNA 3'-end processing (Lianoglou et al. 2013; Xia et al. 2014; Chen et al. 2018a). However, we also find enrichment for pathways and processes implicated in PDAC biology, including protein metabolism, receptor tyrosine kinase signaling, and signaling by RHO GTPases. Indeed, the link between 3'-UTR alterations and cancer metabolism has been identified in previous pan-cancer APA analyses (Xia et al. 2014). We also find an unexpected enrichment for loss of binding sites for tumor-suppressive miRNAs in frequently lost 3'-UTR regions. Therefore, we propose that APA is an underappreciated mechanism of gene dysregulation in PDAC, driving the expression of growth-promoting genes through disruption of miRNA-mediated regulation.

The extent of heterogeneity in proximal PAS usage across cancer patients has been largely overlooked in previous pan-cancer APA analyses. We found little heterogeneity in the extent of 3'-UTR proximal site usage in most genes (including housekeeping genes) in both normal and PDAC samples, again providing evidence for minimal batch effects. However, PDAC patients showed substantial heterogeneity in the extent to which their metabolic genes used the proximal PAS. This metabolic plasticity in turn could serve as a mechanism to deal with the fluctuating metabolic demands of cancer cells. These data support the possibility that APA may drive deregulation of cancer metabolism and tumor evolution by allowing for PAS choice plasticity of critical metabolic genes in PDAC.

Several studies have shown the power of APA analysis to improve expression-based prognostic markers. We report the first subset of 3'-UTR alterations that act as an independent prognostic indicator of PDAC outcome. Although several of the genes in this set are known regulators of tumorigenesis, including *SAT1*, many have not been implicated in PDAC biology and may represent new mediators of cancer phenotypes. The lost miRNA sites are enriched for tumor-suppressive miRNA families. In particular, we observed that patients who retain binding sites for a subset of five

miRNAs survive longer than patients who lose them. This uncovers the prognostic role for a novel subset of miRNA mediators in PDAC.

Our in-depth analysis of APA in PDAC revealed a critical role for the druggable target CSNK1A1 in PDAC cell growth and survival. Although CSNK1A1 regulates Wnt signaling and the TP53 pathway, mediators of PDAC progression, the relevance of CSNK1A1 to PDAC was previously unknown (Järås et al. 2014; Lantermann et al. 2015; Cai et al. 2018; Jiang et al. 2018). Furthermore, the mechanisms of regulation of CSNK1A1 in cancer are not well understood, although promoter methylation in melanoma has been reported (Sinnberg et al. 2010). Two CSNK1A1 isoforms have been detected in HeLa cells, with the shorter isoform being generated from the use of an alternative PAS (Yong et al. 2000). We show that CSNK1A1 exhibits increased expression in PDAC samples as compared to precursors, and that pharmacological and genetic blockade of CSNK1A1 attenuates PDAC cell proliferation and clonogenic growth. Therefore, our single-cancer approach can identify APA-regulated, disease-specific vulnerabilities.

Our computational analysis and experimental validation have revealed unexpected mediators of PDAC biology and broadened our understanding of the regulatory role of 3'-UTR sequence space in cancer. This comprehensive analysis reveals the scope of previously uncharacterized APA events in regulating functionally relevant PDAC genes, improving patient prognosis and driving tumor evolution. We propose that the landscape of 3'-UTR alterations in PDAC represents a novel avenue to better understand PDAC progression and identify new drug targets.

Methods

Data collection and preprocessing

Our study focused on PDAC tumors consistent with the histology of PDAC ($n = 148$). All raw RNA-seq data used in this study were downloaded via NCBI dbGaP after our request for controlled-access data was processed. This included 184 normal pancreas SRA files from GTEx (dbGaP accession phs000424.v8.p2) and 148 BAM files within the TCGA-PAAD cohort (<https://portal.gdc.cancer.gov/>). GTEx SRA files were aligned exactly according to the TCGA RNA-seq alignment pipeline using GENCODE v22 annotations. The bedGraph files were generated using BEDTools v2.26 (Quinlan and Hall 2010) and were supplied as input to the DaPars algorithm.

DaPars analysis

The bedGraph coverage files were processed using DaPars (Python 2.7.13) for de novo identification of differences in 3' UTR between tumor and normal samples. The output of DaPars is a matrix of PDUI scores for every sample (columns) for any given gene (rows). Each cell represented a PDUI score for a gene corresponding to the tumor or normal sample. The PDUI score for a given gene represents the percentage of distal PAS usage in the sample. A higher PDUI score represents greater usage of the distal PAS site. In order to compare 3'-UTR changes for a given gene between tumor and normal samples, the PDUI scores for the gene was averaged over tumor samples (MeanPDUI_T) and normal (MeanPDUI_N) samples. A change in the mean PDUI score between tumor and normal samples for each gene ($\Delta\text{PDUI} = \text{MeanPDUI}_T - \text{MeanPDUI}_N$) was computed as a measure of 3'-UTR differences. The significance of this difference was assessed by the algorithm using Fisher's exact test, which was further adjusted using the Benjamini-Hochberg (BH) procedure (Benjamini and Hochberg 1995) to control the false discovery rate using 0.05 as a threshold to select significant hits. The

final output of our analysis after eliminating redundant transcripts (based on lowest FDR) and selecting for protein-coding transcripts was a matrix containing 2573 unique genes as rows and tumor/normal sample in each column (total 148 tumor+184 normal=332 columns). Given that our samples are not matched, we did not generate a Δ PDI value for a given gene for every sample, rather we have a unique Δ PDI value for every outputted gene. A similar analysis was performed with a subset of 69 high purity PDAC tumor samples (The Cancer Genome Atlas Research Network 2017).

Bioinformatics analyses and statistical methods

Analysis of heterogeneity

The variance in PDI scores across tumor samples ($\text{Var}[\text{Tumor}]$) as well as normal samples ($\text{Var}[\text{Normal}]$) was computed for every gene as a measure of its heterogeneity in PAS site usage across samples. The difference in variance/heterogeneity between the two data sets ($\text{Var}[\text{Normal}] - \text{Var}[\text{Tumor}]$) was plotted (R version 3.6.0) (R Core Team 2014). The significance of the difference for each gene was assessed using an F test of variances.

Heatmap analysis

A heatmap representing the extent of 3'-UTR alterations across PDAC patients was generated (R version 3.6.0). Given that we do not have a Δ PDI value for each patient, we computed an estimate of Δ PDI associated with each patient for any given gene, using the following approach. For each significant gene hit ($|\Delta\text{PDI}| > 0.1$, row in heatmap), the mean GTEX PDI score was subtracted from the PDI score for each TCGA PDAC patient to obtain a measure of $\Delta\text{PDI}_{\text{patient}}$ (change in 3'-UTR length for that gene for each patient). We implemented unsupervised hierarchical clustering using Ward's minimum variance method, to minimize the inter-cluster Euclidean distances. Rows were similarly clustered to yield subsets of genes undergoing a higher degree of 3'-UTR shortening (red) or lengthening (blue). Five distinct subgroups are presented to visualize the patterns of widespread 3'-UTR shortening among patients. The mutational status of commonly altered PDAC genes and PDAC subtype for each TCGA patient was highlighted (The Cancer Genome Atlas Research Network 2017).

Survival analysis

We first fit a complex clinical model including diagnosis age, stage, grade, residual tumor, sex, and race. Residuals from this model reflect signal not explained by the standard clinical subspace. PDI scores associated with the residuals were then screened to identify a multivariate subspace to study. We selected 20 features (genes) to study based on P -value order. Using repeated random starts, we selected $K=3$ k -means clustering based on the elbow heuristic to define three prognosis groups based on the within/between sum of squares criterion. The prognostic value of this classification is described by standard Kaplan–Meier plot and the log-rank test. We determined that 85% of random restarts led to statistically significant log-rank tests for $K=3$ suggesting that significant additional prognostic information in the PDI subspace above the clinical data was stable as opposed to stochastic clustering.

Percentage of lost miRNA sites

Highly conserved miRNA binding sites and their genomic positions were downloaded from TargetScanHuman 7.2. This list, along with DaPars prediction of genomic coordinates of lost 3' UTRs was used to plot the number of genes that lose at least one highly conserved miRNA binding site.

miRNA families preferentially associate with lost sites

To determine miRNAs associated with sites enriched in lost 3' UTRs, miRNA target predictions and the cumulative weighted context++ scores (CWCS) were downloaded from TargetScanHuman 7.2. CWCS estimates the predicted cumulative repression for a miRNA at the site. The lost miRNA binding sites in the shortened 3' UTRs of PDAC patients were inferred from DaPars predictions. A weighted target site score was computed as the sum over all genes with shortened 3' UTRs in tumor, with the CWCS of each target site for the miRNA multiplied by the normalized abundance of the gene's 3'-UTR form in which the predicted target site was present. The fold change (f) of the sum of weighted target site scores in lost 3'-UTR regions for PDAC tumor over normal was calculated ($f = \text{score in tumor} / \text{score in normal}$). The labels of the miRNA target sites were permuted to assess the significance of the fold change. One thousand such randomizations were performed and the mean (m) and standard deviation (s) of the fold changes across the randomized data sets was computed. The significance of the fold change was computed in form of the Z -score defined as $(f - m) / s$. A lower Z -score indicates that the loss in miRNA binding sites is higher than that expected by chance.

miRNA prognostic signature

We quantified the impact of APA-based loss of miRNA binding as follows:

$$X_{m,i} = \sum_g (1 - \text{PDI}_{i,g}) \times A_{g,m},$$

where $A_{g,m}$ is an indicator function that the short versus long 3' UTR of the gene g contains the binding site for miRNA m , the impact to the i th person is $X_{m,i}$. We used Sure Independence Screening (SIS) to search through all affected miRNAs and identify features that were associated with survival univariately (Fan and Lv 2008). To study the multivariate effect, we reorganized cases using the Euclidean distance between SIS selected features, visualized with t -SNE, and defined clusters with model-based Gaussian clustering using the BIC criterion to select cluster number. Survival differences were tested across all groups by the log-rank test and were visualized by Kaplan–Meier estimate. We performed the analysis of deviance test of the nested Cox regression model: clinical variables versus clinical variables + miRNA clusters which was statistically significant ($P=0.02$) suggesting that addition of miRNA clusters improved the model. The pattern of loss of miRNA binding sites across patient clusters was visualized for a subset of miRNAs in a heatmap.

Experimental methods

Cell lines and general reagents

MIA PaCa-2 and HEK293 cells were purchased from ATCC and cultured in DMEM media (Corning MT 10-013-CV) and 10% fetal bovine serum. Suit2 cells were obtained from Dr. David Tuveson (Cold Spring Harbor Laboratory). Cell lines were periodically verified to be mycoplasma free using the MycoAlert kit (Lonza LT07-701). All transfections were carried out using Lipofectamine 3000 (Thermo Fisher Scientific L3000008) per the manufacturer's protocol.

3' RACE assays

cDNA was generated from 1 μ g RNA from MIA PaCa-2 as well as Suit2 cell lines using SuperScript II Reverse Transcriptase (Thermo Fisher Scientific 18064022) using the primer P: 5'-GAC TCGAGTCGACATCGATTTTTTTTTTTTTTTTTTTT-3'. To PCR amplify

the 3'-UTR forms of candidate genes, a gene-specific forward primer spanning the stop codon of the gene was used in conjunction with a reverse primer P': 5'-GACTCGAGTCGACATCG-3' targeting the adapter region introduced by primer P. The PCR mixture was run on a 1.5% agarose gel and visualized using the ChemiDoc imaging system followed by analysis with Image Lab software (Version 6.0.0, Bio-Rad). An identical cDNA generation and PCR procedure was followed for RNA extracted from PDAC patient tumor samples. RNA from PDAC patient samples were obtained from Roswell Park Pathology Shared Resource. Approval of biospecimen use was granted by the Roswell Park IRB.

Luciferase reporter assays

MIA PaCa-2 cells were seeded at ~10,000 cells per well in a 96-well white plate (Thermo Fisher Scientific 07-200-628). Three technical replicates were plated for each condition. The cells were transfected the next day at ~60% confluency with 200 ng of *Renilla* luciferase reporter plasmid (pIS1 containing the 3'-UTR region of interest) (Supplemental Table S1) and 2 ng of firefly luciferase reporter control plasmid pIS0 per well. In cases in which the 3'-UTR lengths between the short and long form were significantly different, we ensured that equal molar amounts of the 3'-UTR constructs were transfected. Luciferase readings were measured 24 h post-transfection with the Dual luciferase reporter assay system (Promega E1910) using the Synergy H1 plate reader. The *Renilla* reporter reading was normalized to its corresponding firefly reading in every well to control for transfection efficiency.

Statistical analyses

All experimental findings presented were replicated in three or more independent experiments. Comparisons between two groups were performed using unpaired *t*-test with Welch's correction in GraphPad Prism 8. In general, $P < 0.05$ was considered significant, and the determined *P*-values are provided in the figure legends. Asterisks in graphs denote statistically significant differences as described in figure legends.

Software availability

The code to preprocess RNA-seq data as well as the R code for all analyses is provided as Supplemental Code and is also available at GitHub (https://github.com/feiginlab/APA_PDA).

Competing interest statement

The authors declare no competing interests.

Acknowledgments

This work was supported by National Cancer Institute (National Institutes of Health) grants P30 CA016056 and R25 CA181003, an award from the Roswell Park Alliance Foundation to M.E.F., U.S. Department of Defense grant OC170368 to K.H.E., and scholarship and support to A.A.A. from Prince Sattam bin Abdulaziz University in Saudi Arabia, Saudi Arabian Cultural Mission in U.S., and the Office of International Collaborations in Oncology at Roswell Park Comprehensive Cancer Center. We thank the Roswell Park Gene Modulation core, Pathology Shared Resource, Genomics Shared Resource, and the Small Molecule Screening Shared Resource for their assistance. We thank the members of the Feigin Laboratory, the Roswell Park Department of Pharmacology and Therapeutics, and the Science Twitter community for their helpful comments on the manuscript.

Author contributions: S.V. and M.E.F. wrote the manuscript. M.E.F. supervised the study. S.V. performed the DaPars analysis. S.V., A.A.T., J.R.S., and A.A.A. performed biological experiments. S.V., K.H.E., H.C.M., and K.P.O. contributed to data analysis. K.H.E. developed prognostic signatures.

References

- Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, Goga A, Sirota M, Butte AJ. 2017. Comprehensive analysis of normal adjacent to tumor transcriptomes. *Nat Commun* **8**: 1077. doi:10.1038/s41467-017-01027-z
- Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al. 2016. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* **531**: 47–52. doi:10.1038/nature16965
- Baradaran B, Shahbazi R, Khordadmehr M. 2019. Dysregulation of key microRNAs in pancreatic cancer development. *Biomed Pharmacother* **109**: 1008–1015. doi:10.1016/j.biopha.2018.10.177
- Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B* **57**: 289–300. doi:10.1111/j.2517-6161.1995.tb02031.x
- Boutet SC, Cheung TH, Quach NL, Liu L, Prescott SL, Edalati A, Iori K, Rando TA. 2012. Alternative polyadenylation mediates microRNA regulation of muscle stem cell function. *Cell Stem Cell* **10**: 327–336. doi:10.1016/j.stem.2012.01.017
- Brett-Morris A, Wright BM, Seo Y, Pasupuleti V, Zhang J, Lu J, Spina R, Bar EE, Gujrati M, Schur R, et al. 2014. The polyamine catabolic enzyme SAT1 modulates tumorigenesis and radiation response in GBM. *Cancer Res* **74**: 6925–6934. doi:10.1158/0008-5472.CAN-14-1249
- Brumbaugh J, Di Stefano B, Wang X, Borkent M, Forouzmand E, Clowers KJ, Ji F, Schwarz BA, Kalocsay M, Elledge SJ, et al. 2018. Nudt21 controls cell fate by connecting alternative polyadenylation to chromatin signaling. *Cell* **172**: 106–120.e21. doi:10.1016/j.cell.2017.11.023
- Cai J, Li R, Xu X, Zhang L, Lian R, Fang L, Huang Y, Feng X, Liu X, Li X, et al. 2018. CK1 α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy. *Nat Cell Biol* **20**: 465–478. doi:10.1038/s41556-018-0065-8
- The Cancer Genome Atlas Research Network. 2017. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* **32**: 185–203.e13. doi:10.1016/j.ccell.2017.07.007
- The Cancer Genome Atlas Research Network, Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, Ally A, Balasundaram M, Birol I, et al. 2013. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* **45**: 1113–1120. doi:10.1038/ng.2764
- Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, Zhou W, Petricoin EF, Cappello P, Novelli F. 2016. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. *Oncotarget* **7**: 5598. doi:10.18632/oncotarget.6798
- Chen M, Lyu G, Han M, Nie H, Shen T, Chen W, Niu Y, Song Y, Li X, Li H, et al. 2018a. 3' UTR lengthening as a novel mechanism in regulating cellular senescence. *Genome Res* **28**: 285–294. doi:10.1101/gr.224451.117
- Chen X, Zhang JX, Luo JH, Wu S, Yuan GJ, Ma NF, Feng Y, Cai MY, Chen RX, Lu J, et al. 2018b. CSTF2-induced shortening of the *RAC1* 3'UTR promotes the pathogenesis of urothelial carcinoma of the bladder. *Cancer Res* **78**: 5848–5862. doi:10.1158/0008-5472.CAN-18-0822
- Chien Y, White MA. 2003. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. *EMBO Rep* **4**: 800–806. doi:10.1038/sj.embor.embor899
- Chu Y, Elrod N, Wang C, Li L, Chen T, Routh A, Xia Z, Li W, Wagner EJ, Ji P. 2019. *Nudt21* regulates the alternative polyadenylation of *Pak1* and is predictive in the prognosis of glioblastoma patients. *Oncogene* **38**: 4154–4168. doi:10.1038/s41388-019-0714-9
- Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. 2011. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. *Nat Med* **17**: 500–503. doi:10.1038/nm.2344
- Dangi-Garimella S, Strouch MJ, Grippo PJ, Brentem DJ, Munshi HG. 2011. Collagen regulation of *let-7* in pancreatic cancer involves TGF- β 1-mediated membrane type 1-matrix metalloproteinase expression. *Oncogene* **30**: 1002–1008. doi:10.1038/onc.2010.485
- D'Antonio M, Weghorn D, D'Antonio-Chronowska A, Coulet F, Olson KM, DeBoever C, Drees F, Arias A, Alakus H, Richardson AL, et al. 2017. Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer. *Nat Commun* **8**: 436. doi:10.1038/s41467-017-00100-x
- Dey P, Rachagani S, Vaz AP, Ponnusamy MP, Batra SK. 2014. PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia. *Oncotarget* **5**: 4480–4491. doi:10.18632/oncotarget.2041

- Easwaran H, Tsai HC, Baylin SB. 2014. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. *Mol Cell* **54**: 716–727. doi:10.1016/j.molcel.2014.05.015
- Eisenberg E, Levanon EY. 2003. Human housekeeping genes are compact. *Trends Genet* **19**: 362–365. doi:10.1016/S0168-9525(03)00140-9
- Eisenberg E, Levanon EY. 2013. Human housekeeping genes, revisited. *Trends Genet* **29**: 569–574. doi:10.1016/j.tig.2013.05.010
- Elkon R, Ugalde AP, Agami R. 2013. Alternative cleavage and polyadenylation: extent, regulation and function. *Nat Rev Genet* **14**: 496–506. doi:10.1038/nrg3482
- Erson-Bensan AE, Can T. 2016. Alternative polyadenylation: another foe in cancer. *Mol Cancer Res* **14**: 507–517. doi:10.1158/1541-7786.MCR-15-0489
- Fahrman JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, Vykoukal J, Kundnani DL, Foretova L, et al. 2019. A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer. *J Natl Cancer Inst* **111**: 372–379. doi:10.1093/jnci/djy126
- Fan J, Lv J. 2008. Sure independence screening for ultrahigh dimensional feature space. *J R Stat Soc Ser B* **70**: 849–911. doi:10.1111/j.1467-9868.2008.00674.x
- Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, et al. 2017. Recurrent non-coding regulatory mutations in pancreatic ductal adenocarcinoma. *Nat Genet* **49**: 825–833. doi:10.1038/ng.3861
- Feng X, Li L, Wagner EJ, Li W. 2017. TC3A: The Cancer 3' UTR Atlas. *Nucleic Acids Res* **46**: D1027–D1030. doi:10.1093/nar/gkx892
- Grassi E, Mariella E, Lembo A, Molineris I, Provero P. 2016. Roar: detecting alternative polyadenylation with standard mRNA sequencing libraries. *BMC Bioinformatics* **17**: 423. doi:10.1186/s12859-016-1254-8
- Gruber AJ, Zavolan M. 2019. Alternative cleavage and polyadenylation in health and disease. *Nat Rev Genet* **20**: 599–614. doi:10.1038/s41576-019-0145-z
- The GTEx Consortium. 2015. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**: 648–660. doi:10.1126/science.1262110
- Hinohara K, Polyak K. 2019. Intratumoral heterogeneity: more than just mutations. *Trends Cell Biol* **29**: 569–579. doi:10.1016/j.tcb.2019.03.003
- Hsu CC, Leu YW, Tseng MJ, Lee KD, Kuo TY, Yen JY, Lai YL, Hung YC, Sun WS, Chen CM, et al. 2011. Functional characterization of *Trip10* in cancer cell growth and survival. *J Biomed Sci* **18**: 12. doi:10.1186/1423-0127-18-12
- Hu Y, Ou Y, Wu K, Chen Y, Sun W. 2012. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. *Tumor Biol* **33**: 1863–1870. doi:10.1007/s13277-012-0446-8
- Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, et al. 2014. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. *J Exp Med* **211**: 605–612. doi:10.1084/jem.20131033
- Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi S, Jin K, Liang D, Xu W, Xu H, et al. 2016. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. *Cancer Lett* **374**: 127–135. doi:10.1016/j.canlet.2016.01.054
- Jiang S, Zhang M, Sun J, Yang X. 2018. Casein kinase 1 α : biological mechanisms and theranostic potential. *Cell Commun Signal* **16**: 23. doi:10.1186/s12964-018-0236-z
- Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* **321**: 1801–1806. doi:10.1126/science.1164368
- Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, et al. 2015. Personalized genomic analyses for cancer mutation discovery and interpretation. *Sci Transl Med* **7**: 283ra53. doi:10.1126/scitranslmed.aaa7161
- Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT. 2010. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. *Genes Dev* **24**: 2754–2759. doi:10.1101/gad.1950610
- Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, Sboner A, Lochovsky L, Chen J, Harmanci A, et al. 2013. Integrative annotation of variants from 1092 humans: application to cancer genomics. *Science* **342**: 1235587. doi:10.1126/science.1235587
- Knippschild U, Gocht A, Wolff S, Huber N, Löhler J, Stöter M. 2005. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. *Cell Signal* **17**: 675–689. doi:10.1016/j.cellsig.2004.12.011
- Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, et al. 2012. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. *Br J Cancer* **106**: 405–413. doi:10.1038/bjc.2011.462
- Kosti I, Jain N, Aran D, Butte AJ, Sirota M. 2016. Cross-tissue analysis of gene and protein expression in normal and cancer tissues. *Sci Rep* **6**: 24799. doi:10.1038/srep24799
- Lackford B, Yao C, Charles GM, Weng L, Zheng X, Choi EA, Xie X, Wan J, Xing Y, Freudenberger JM, et al. 2014. Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. *EMBO J* **33**: 878–889. doi:10.1002/emboj.201386537
- Lantermann AB, Chen D, McCutcheon K, Hoffman G, Frias E, Ruddy D, Rakiec D, Korn J, McAllister G, Stegmeier F, et al. 2015. Inhibition of casein kinase 1 α prevents acquired drug resistance to erlotinib in EGFR-mutant non-small cell lung cancer. *Cancer Res* **75**: 4937–4948. doi:10.1158/0008-5472.CAN-15-1113
- Lappalainen T, Sammeth M, Friedländer MR, 't Hoen PA, Monlong J, Rivas MA, González-Porta M, Kurbatova N, Griebel T, Ferreira PG, et al. 2013. Transcriptome and genome sequencing uncovers functional variation in humans. *Nature* **501**: 506–511. doi:10.1038/nature12531
- Lee YS, Dutta A. 2007. The tumor suppressor microRNA *let-7* represses the HMG2 oncogene. *Genes Dev* **21**: 1025–1030. doi:10.1101/gad.1540407
- Le Pera L, Mazzapioda M, Tramontano A. 2015. 3USS: a web server for detecting alternative 3'UTRs from RNA-seq experiments. *Bioinformatics* **31**: 1845–1847. doi:10.1093/bioinformatics/btv035
- Li C, Yu S, Nakamura F, Yin S, Xu J, Petrolla AA, Singh N, Tartakoff A, Abbott DW, Xin W, et al. 2009. Binding of pro-prior to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. *J Clin Invest* **119**: 2725–2736. doi:10.1172/JCI39542
- Li L, Wang D, Xue M, Mi X, Liang Y, Wang P. 2015. 3'UTR shortening identifies high-risk cancers with targeted dysregulation of the ceRNA network. *Sci Rep* **4**: 5406. doi:10.1038/srep05406
- Lianoglou S, Garg V, Yang JL, Leslie CS, Mayr C. 2013. Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. *Genes Dev* **27**: 2380–2396. doi:10.1101/gad.229328.113
- Lomber G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, et al. 2018. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. *Nat Commun* **9**: 1978. doi:10.1038/s41467-018-04383-6
- Masamha CP, Xia Z, Yang J, Albrecht TR, Li M, Shyu A-B, Li W, Wagner EJ. 2014. CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. *Nature* **510**: 412–416. doi:10.1038/nature13261
- Matoulova E, Michalova E, Vojtesek B, Hrstka R. 2012. The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells. *RNA Biol* **9**: 563–576. doi:10.4161/ma.20231
- Maurer HC, Olive KP. 2019. Laser capture microdissection on frozen sections for extraction of high-quality nucleic acids. *Methods Mol Biol* **1882**: 253–259. doi:10.1007/978-1-4939-8879-2_23
- Maurer C, Holmstrom SR, He J, Laise P, Su T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, et al. 2019. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. *Gut* **68**: 1034–1043. doi:10.1136/gutjnl-2018-317706
- Mayr C. 2016. Evolution and biological roles of alternative 3'UTRs. *Trends Cell Biol* **26**: 227–237. doi:10.1016/j.tcb.2015.10.012
- Mayr C. 2019. What are 3'UTRs doing? *Cold Spring Harb Perspect Biol* **11**: a034728. doi:10.1101/cshperspect.a034728
- Mayr C, Bartel DP. 2009. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell* **138**: 673–684. doi:10.1016/j.cell.2009.06.016
- Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between *let-7* and *Hmg2* enhances oncogenic transformation. *Science* **315**: 1576–1579. doi:10.1126/science.1137999
- McGranahan N, Swanton C. 2017. Clonal heterogeneity and tumor evolution: past, present, and the future. *Cell* **168**: 613–628. doi:10.1016/j.cell.2017.01.018
- Mihaljevic AL, Michalski CW, Friess H, Kleeff J. 2010. Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis. *Langenbeck's Arch Surg* **395**: 295–308. doi:10.1007/s00423-010-0622-5
- Miles WO, Lembo A, Volorio A, Brachtel E, Tian B, Sgroi D, Provero P, Dyson N. 2016. Alternative polyadenylation in triple-negative breast tumors allows NRAS and c-JUN to bypass PUMILIO posttranscriptional regulation. *Cancer Res* **76**: 7231–7241. doi:10.1158/0008-5472.CAN-16-0844
- Mitra M, Johnson EL, Swamy VS, Nersesian LE, Corney DC, Robinson DG, Taylor DG, Ambrus AM, Jelinek D, Wang W, et al. 2018. Alternative polyadenylation factors link cell cycle to migration. *Genome Biol* **19**: 176. doi:10.1186/s13059-018-1551-9
- Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al. 2015. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Genet* **47**: 1168–1178. doi:10.1038/ng.3398

- Nimmakayala RK, Seshacharyulu P, Lakshmanan I, Rachagani S, Chugh S, Karmakar S, Rauth S, Vengoji R, Atri P, Talmon GA, et al. 2018. Cigarette smoke induces stem cell features of pancreatic cancer cells via PAF1. *Gastroenterology* **155**: 892–908.e6. doi:10.1053/j.gastro.2018.05.041
- Park HJ, Ji P, Kim S, Xia Z, Rodriguez B, Li L, Su J, Chen K, Masamha CP, Baillat D, et al. 2018. 3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. *Nat Genet* **50**: 783–789. doi:10.1038/s41588-018-0118-8
- Passacantilli I, Panzeri V, Bielli P, Farini D, Pillozzi E, Fave GD, Capurso G, Sette C. 2017. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. *Cell Death Dis* **8**: e3168. doi:10.1038/cddis.2017.562
- Pereira B, Billaud M, Almeida R. 2017. RNA-binding proteins in cancer: old players and new actors. *Trends Cancer* **3**: 506–528. doi:10.1016/j.trecan.2017.05.003
- Pham H, Ekaterina Rodriguez C, Donald GW, Hertzner KM, Jung XS, Chang H-H, Moro A, Reber HA, Hines OJ, Eibl G. 2013. miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. *Biochem Biophys Res Commun* **439**: 6–11. doi:10.1016/j.bbrc.2013.08.042
- Phanstiel O. 2018. An overview of polyamine metabolism in pancreatic ductal adenocarcinoma. *UICC Int J Cancer IJC* **142**: 1968–1976. doi:10.1002/ijc.31155
- Proudfoot NJ. 2011. Ending the message: poly(A) signals then and now. *Genes Dev* **25**: 1770–1782. doi:10.1101/gad.17268411
- Qin Y, Dang X, Li W, Ma Q. 2014. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. *Oncol Res Featur Preclin Clin Cancer Ther* **21**: 353–363. doi:10.3727/096504014X14024160459122
- Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**: 841–842. doi:10.1093/bioinformatics/btq033
- R Core Team. 2014. *R: a language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna. <http://www.R-project.org/>.
- Rena G, Bain J, Elliott M, Cohen P. 2004. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. *EMBO Rep* **5**: 60–65. doi:10.1038/sj.embor.7400048
- Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, et al. 2017. Recurrent and functional regulatory mutations in breast cancer. *Nature* **547**: 55–60. doi:10.1038/nature22992
- Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. 2008. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. *Science* **320**: 1643–1647. doi:10.1126/science.1155390
- Schitteck B, Sinnberg T. 2014. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. *Mol Cancer* **13**: 231. doi:10.1186/1476-4598-13-231
- Schultz NA, Dehlendorf C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, et al. 2014. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. *JAMA* **311**: 392. doi:10.1001/jama.2013.284664
- Seshacharyulu P, Pandey P, Datta K, Batra SK. 2013. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. *Cancer Lett* **335**: 9–18. doi:10.1016/j.canlet.2013.02.036
- Shi Y, Manley JL. 2015. The end of the message: multiple protein-RNA interactions define the mRNA polyadenylation site. *Genes Dev* **29**: 889–897. doi:10.1101/gad.261974.115
- Siegel RL, Miller KD, Jemal A. 2017. Cancer statistics, 2017. *CA Cancer J Clin* **67**: 7–30. doi:10.3322/caac.21387
- Sinnberg T, Menzel M, Kaesler S, Biedermann T, Sauer B, Nahnsen S, Schwarz M, Garbe C, Schitteck B. 2010. Suppression of casein kinase 1 α in melanoma cells induces a switch in β -catenin signaling to promote metastasis. *Cancer Res* **70**: 6999–7009. doi:10.1158/0008-5472.CAN-10-0645
- Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H, Wu J, Kang Y, Zhao J, Yu Q, et al. 2018. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. *Oncogene* **37**: 4887–4900. doi:10.1038/s41388-018-0280-6
- Tian B, Manley JL. 2017. Alternative polyadenylation of mRNA precursors. *Nat Rev Mol Cell Biol* **18**: 18–30. doi:10.1038/nrm.2016.116
- Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, et al. 2018. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. *Cancer Discov* **8**: 1112–1129. doi:10.1158/2159-8290.CD-18-0349
- Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al. 2009. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. *Hepatology* **49**: 1571–1582. doi:10.1002/hep.22806
- Vandenberg CA. 2008. Integrins step up the pace of cell migration through polyamines and potassium channels. *Proc Natl Acad Sci* **105**: 7109–7110. doi:10.1073/pnas.0803231105
- Vaz AP, Ponnusamy MP, Rachagani S, Dey P, Ganti AK, Batra SK. 2014. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. *Br J Cancer* **111**: 486–496. doi:10.1038/bjc.2014.152
- Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al. 2015. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* **518**: 495–501. doi:10.1038/nature14169
- Wang X, Lu X, Zhang T, Wen C, Shi M, Tang X, Chen H, Peng C, Li H, Fang Y, et al. 2016. miR-329 restricts tumor growth by targeting grb2 in pancreatic cancer. *Oncotarget* **7**: 21441–21453. doi:10.18632/oncotarget.7375
- Wang Q, Wang J, Niu S, Wang S, Liu Y, Wang X, Wang S, Wang S, Liu Y, Liu Y, et al. 2019. MicroRNA-664 targets paired box protein 6 to inhibit the oncogenicity of pancreatic ductal adenocarcinoma. *Int J Oncol* **54**: 1884–1896. doi:10.3892/ijo.2019.4759
- Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. 2014. Genome-wide analysis of noncoding regulatory mutations in cancer. *Nat Genet* **46**: 1160–1165. doi:10.1038/ng.3101
- Wu DH, Liang H, Lu SN, Wang H, Su ZL, Zhang L, Ma JQ, Guo M, Tai S, Yu S. 2018. miR-124 suppresses pancreatic ductal adenocarcinoma growth by regulating monocarboxylate transporter 1-mediated cancer lactate metabolism. *Cell Physiol Biochem* **50**: 924–935. doi:10.1159/000494477
- Xia Z, Donehower LA, Cooper TA, Neilson JR, Wheeler DA, Wagner EJ, Li W. 2014. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. *Nat Commun* **5**: 5274. doi:10.1038/ncomms6274
- Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang X, Mills T, Chen NY, Kim Y, Muge Ozguc F, et al. 2018. Comprehensive characterization of alternative polyadenylation in human cancer. *J Natl Cancer Inst* **110**: 379–389. doi:10.1093/jnci/djx223
- Xue Z, Warren RL, Gibb EA, MacMillan D, Wong J, Chiu R, Hammond SA, Yang C, Nip KM, Ennis CA, et al. 2018. Recurrent tumor-specific regulation of alternative polyadenylation of cancer-related genes. *BMC Genomics* **19**: 536. doi:10.1186/s12864-018-4903-7
- Yaffe MB. 2019. Why geneticists stole cancer research even though cancer is primarily a signaling disease. *Sci Signal* **12**: eaaw3483. doi:10.1126/scisignal.aaw3483
- Ye C, Long Y, Ji G, Li QQ, Wu X, Berger B. 2018. APATrap: identification and quantification of alternative polyadenylation sites from RNA-seq data. *Bioinformatics* **34**: 1841–1849. doi:10.1093/bioinformatics/bty029
- Yong TJ, Gan YY, Toh BH, SENTRY JW. 2000. Human CK1 α_1 and CK1 α_2 are encoded by both 2.4- and 4.2-kb transcripts, the longer containing multiple RNA-destablising elements. *Biochim Biophys Acta* **1492**: 425–433. doi:10.1016/S0167-4781(00)00146-9
- Yu S, Li L, Wu Q, Dou N, Li Y, Gao Y, Dou N, Dou N, Li Y, Li Y, et al. 2018. PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation. *Int J Oncol* **52**: 2011–2020. doi:10.3892/ijo.2018.4329
- Zeng WZD, Glicksberg BS, Li Y, Chen B. 2019. Selecting precise reference normal tissue samples for cancer research using a deep learning approach. *BMC Med Genomics* **12**: 21. doi:10.1186/s12920-018-0463-6
- Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C. 2009. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. *World J Surg* **33**: 698–709. doi:10.1007/s00268-008-9833-0
- Zhou AX, Toylyu A, Nallapalli RK, Nilsson G, Atabay N, Heldin CH, Borén J, Bergo MO, Akyürek LM. 2011. Filamin A mediates HGF/c-MET signaling in tumor cell migration. *Int J Cancer* **128**: 839–846. doi:10.1002/ijc.25417
- Zhu J, He F, Song S, Wang J, Yu J. 2008. How many human genes can be defined as housekeeping with current expression data? *BMC Genomics* **9**: 172. doi:10.1186/1471-2164-9-172

Received September 25, 2019; accepted in revised form February 4, 2020.